CSPC Pharmaceutical Group’s AGM Resolutions Passed Successfully

CSPC Pharmaceutical Group ( (HK:1093) ) has shared an announcement.

CSPC Pharmaceutical Group Limited announced the successful passing of all resolutions at its Annual General Meeting held on May 30, 2025. Key resolutions included the approval of financial statements for 2024, the declaration of a final dividend, re-election of directors, and the granting of mandates for share buy-backs and issuance. These resolutions reflect the company’s strategic direction and commitment to shareholder value, potentially impacting its market positioning and stakeholder confidence.

The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.21 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a Hong Kong-based company operating in the pharmaceutical industry. It is primarily engaged in the development, manufacture, and sale of pharmaceutical products, focusing on innovative drugs and generic drugs.

Average Trading Volume: 159,444,150

Technical Sentiment Signal: Buy

Current Market Cap: HK$78.42B

For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.